



Used in Lieu of PTO/SB/08A/B
(Based on PTO 10-07 version)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/693,538-Conf. #4018
				Filing Date	October 23, 2003
				First Named Inventor	Michele SANICOLA-NADEL
				Art Unit	1643
				Examiner Name	P. K. Tungaturthi
Sheet	1	of	1	Attorney Docket Number	BGN-A117CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/PKT/	A1*	US-5,208,020	05-04-1993	Chari et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/PKT/	B1	WO-02/16413-A2	02-28-2002	Smithkline Beecham Biologicals S.A.		
/PKT/	B2	WO-02/088170-A2	11-07-2002	Biogen, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/PKT/	C1	Ciardiello, Fortunato et al., "Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A," <i>Journal of the National Cancer Institute</i> , Vol. 88(23):1770-1776 (1996)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Parithosh K Tungaturthi/	Date Considered	01/07/2008
-----------------------	---------------------------	--------------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/693538-Conf. #4018
				Filing Date	October 23, 2003
				First Named Inventor	Michele SANICOLA-NADEL
				Art Unit	1643
				Examiner Name	P. K. Tungaturthi
Sheet	2	of	2	Attorney Docket Number	BGNA117CN

PKT		7:617-622 (1995)	
PKT	C6	Ebert, Andreas D., et al., "Cripto-1 Induces Phosphatidylinositol 3'-Kinase-dependent Phosphorylation of AKT and Glycogen Synthase Kinase 3 β in Human Cervical Carcinoma Cells," <i>Cancer Research</i> , Vol. 59:4502-4505 (1999)	
	C7	Kannan, Subha, et al., "Cripto Enhances the Tyrosine Phosphorylation and Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells," <i>The Journal of Biological Chemistry</i> , Vol. 272(6):3330-3335 (1997)	
	C8	Normanno, Nicola, et al., "Expression of amphiregulin, cripto-1, and heregulin α in human breast cancer cells," <i>International Journal of Oncology</i> , Vol. 2:903-911 (1993)	
	C9	Saeki, Toshiaki, et al., "Expression of cripto-1 in human colorectal adenomas and carcinomas is related to the degree of dysplasia," <i>International Journal of Oncology</i> , Vol. 5:445-451 (1994)	
	C10	Saeki, Toshiaki, et al., "Immunohistochemical detection of cripto-1, amphiregulin and transforming growth factor alpha in human gastric carcinomas and intestinal metaplasias," <i>International Journal of Oncology</i> , Vol. 5:215-223 (1994)	
	C11	Salomon, D.S., et al., "The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer," <i>Endocrine-Related Cancer</i> , Vol. 7:199-226 (2000)	
	C12	International Search Report Application No. PCT/US02/11950, dated September 5, 2003	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature.	/Parithosh K Tungaturthi/	Date Considered	10/26/2006
---------------------	---------------------------	-----------------	------------